Maze Therapeutics, Inc. (NASDAQ:MAZE – Get Free Report) shares were up 4.8% during mid-day trading on Tuesday . The company traded as high as $12.13 and last traded at $12.04. Approximately 31,787 shares traded hands during trading, a decline of 87% from the average daily volume of 244,637 shares. The stock had previously closed at $11.49.
Analyst Ratings Changes
A number of analysts recently issued reports on MAZE shares. JPMorgan Chase & Co. started coverage on Maze Therapeutics in a report on Tuesday, February 25th. They set an “overweight” rating and a $30.00 price objective on the stock. Leerink Partners began coverage on Maze Therapeutics in a report on Tuesday, February 25th. They issued an “outperform” rating and a $28.00 price target on the stock. Guggenheim began coverage on Maze Therapeutics in a report on Tuesday, February 25th. They issued a “buy” rating and a $19.00 price target on the stock. TD Cowen raised Maze Therapeutics to a “strong-buy” rating in a report on Tuesday, February 25th. Finally, Leerink Partnrs raised Maze Therapeutics to a “strong-buy” rating in a report on Tuesday, February 25th. Three research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Maze Therapeutics currently has a consensus rating of “Buy” and an average target price of $25.67.
Check Out Our Latest Stock Report on MAZE
Maze Therapeutics Trading Up 7.1 %
Maze Therapeutics Company Profile
We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.
Featured Stories
- Five stocks we like better than Maze Therapeutics
- What Are Earnings Reports?
- Arqit Stock Soars as NVIDIA’s GTC Fuels Quantum Excitement
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- 3 Must-Own Stocks to Build Wealth This Decade
- How to Calculate Return on Investment (ROI)
- Advanced Micro Devices Eyes AI Market Growth—Is AMD a Buy?
Receive News & Ratings for Maze Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maze Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
